FDA RECALLS & COURT ACTIONS: Sept. 9, 1992
Executive Summary
CLASS II -- ACETAMINOPHEN 325 mg tablets, Regular Strength Non-Aspirin Pain Reliever. Recall number: D-481-2. Lot number OE449, exp. date August 1993. Manufacturer: Life-Line Pharmaceuticals, Hayward, California. Recalled by: Manufacturer by letter June 24, 1992. Firm-initiated recall ongoing. Distribution: Pennsylvania and Tennessee; 6,462 units were distributed. Reason: Presence of metal shavings. CLASS II -- BULK NEOMYCIN SULFATE (POWDER), USP Recall number: D-479-2. Lot numbers: 765FY, 430HR; 073HT; 177FU; 178FU. Manufacturer: UpJohn Company, Kalamazoo, Michigan. Recalled by: Manufacturer by letter Aug. 18, 1992. Distribution: Nationwide and International; approximately 4,035 Kilograms were distributed. Reason: Elevated levels of sodium fluoride.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth